– USA, IN – MBX Biosciences, a drug discovery company focused on rare endocrine diseases, today announced the closing of a $34.6 million Series A financing led by Frazier Healthcare Partners, with participation from OrbiMed, New Enterprise Associates, Indiana Philanthropic Venture Fund, Indiana Seed Fund III and Twilight Venture Partners II.
In conjunction with the financing, MBX has appointed three new members to its board of directors: Patrick Heron, managing partner of Frazier Healthcare Partners; Dr. Carl Gordon, Ph.D., managing partner of OrbiMed; and Ed Mathers, general partner of New Enterprise Associates. They join Mr. Hawryluk and Dr. DiMarchi.
Proceeds of the financing will support MBX as it advances its preclinical pipeline of peptide therapeutic candidates directed at clinically-validated molecular targets. The company is built upon the medicinal expertise and chemical technologies invented at the Indiana University laboratory of Professor Richard DiMarchi, Ph.D., co-founder and CSO. The company seeks to address rare endocrine disorders with a substantial unmet medical need.
“With the support of these leading life science investors, we are equipped to advance our drug candidates toward clinical investigation in underserved disease areas,” said Kent Hawryluk, president and CEO. “We are excited to assemble a team with a proven track record in discovering and developing novel drugs to address unmet medical needs.”
“Following the successful history of Marcadia Biotech and Calibrium with Richard and Kent, Frazier is proud to fund the next stage of MBX’s development,” said Mr. Heron. “Together with OrbiMed and NEA, we look forward to helping build another world-class drug development company in Indianapolis with this leadership team.”
About MBX Biosciences
MBX Biosciences is a biotechnology company creating therapies for rare endocrine diseases. Members of MBX’s leadership team previously collaborated in the creation of highly successful endocrine drugs and three Indiana-based companies. MBX is strengthened by world-class proprietary technology and drug candidates licensed from the DiMarchi Indiana University laboratory. The company is supported by investment from leading life science investors that include Frazier Healthcare Partners, OrbiMed, and New Enterprise Associates.
For more information: https://www.mbxbio.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.